Key Highlights

  • Elixinol plans an all-scrip Acquisition of Vitable, a personalised supplement subscription platform, subject to a November Shareholder vote.
  • Q3 FY26 sales Revenue was $3.6 million, and management is targeting combined annual revenue above $20 million on a proforma 2026 basis.
  • Cash was $927,000 at 30 September, with an estimated 3.1 quarters of funding and about $4.0 million of Debt drawn.
  • The company sold its US Business to Ananda Health for headline consideration of about A$465,000 in September.

Elixinol Wellness (ASX:EXL) has spent 2026 shrinking itself into a purely Australian health foods and supplements business, and its next step is a proposed all-scrip acquisition of Vitable, a personalised supplement subscription platform. According to its September quarter activities report and Appendix 4C, released on 14 October 2026, the deal is subject to shareholder approval at a general meeting the company expects to hold in November 2026.

The case for the deal rests on scale. Elixinol reported Q3 FY26 sales revenue of $3.6 million, while Vitable is said to have generated more than $5 million over the last twelve months. Management is targeting combined annual revenue above $20 million on a proforma 2026 basis. The company paired that ambition with a thin balance sheet: $0.93 million in cash at 30 September.

From US hemp to an Australian portfolio

Elixinol was once best known for US CBD products. It completed the sale of its US business to Ananda Health on 4 September 2026 for headline consideration of about A$465,000, of which A$250,000 was upfront and up to A$215,000 is deferred or contingent. What remains are brands including The Healthy Chef, Mt Elephant and Hemp Foods Australia, plus the Australian Primary Hemp bulk ingredients business.

The Quarterly Report showed revenue up 6% on the prior corresponding period, a gross Margin of 42% and operating expenses 26% lower. The Healthy Chef contributed $0.87 million in revenue as its Priceline Pharmacy rollout continued. In a separate update on 13 October, the company said combined branded and bulk hemp sales reached $6.41 million in the nine months to September (unaudited), with full Supply of two major grocery programmes via trade partners running into 2027. On 28 October it launched a Creatine + Electrolytes range under The Healthy Chef brand.

The Vitable terms

The binding agreement, signed on 24 September 2026, involves $2.5 million of Equity paid in five tranches, plus a performance-based "Platform Kicker". The company has set a longer-term target of A$27 million in revenue and A$3 million in EBITDA by 2028, conditional on the earn-out terms being fully realised. These are company targets, not forecasts that have been independently tested. Because the consideration is scrip, existing holders should expect dilution if the deal is approved.

Cash, debt and runway

The Appendix 4C reported net operating cash outflow of $323,000 for the quarter and $1.04 million for the year to date. Cash stood at $927,000, with $79,000 of unused facilities, giving total available funding of $1.0 million and an estimated 3.1 quarters of funding. The company also describes underlying operating cash flow, which excludes finance costs and certain one-off items, as positive for a fourth consecutive quarter; that is a non-statutory measure.

Elixinol carries meaningful debt. About $4.0 million of its $4.04 million in facilities was drawn at quarter end, including ScotPac trade debtor and trade finance lines secured over a Subsidiary at about 11.27% interest, and $505,000 of remaining Loan notes at 15% due to be repaid by 31 March 2027.

Risks and what to watch

The main risks are deal execution and integration, dilution from the scrip consideration, reliance on a small number of retail and grocery programmes, and the refinancing of short-dated, high-interest debt. The confirmed near-term milestone is the general meeting to vote on Vitable, which the company expects in November. The notice of meeting, any independent expert view and the December quarter Appendix 4C will show whether the improvement in margins carries through to statutory cash flow.